|Articles|October 1, 1996

October 1996
Volume 2
Issue 9

Estimating Prevalence and Detection Cost: Prerequisites for Disease State Management of Attention Deficit Hyperactivity Disorder

Download PDF: Estimating Prevalence and Detection Cost: Prerequisites for Disease State Management of Attention Deficit Hyperactivity Disorder

Articles in this issue

over 29 years ago

Article

Use of a New Antiepileptic Drug in an HMO: Economic Outcomes from the Payer Perspective

over 29 years ago

Article

The Influence of New Devices on the Costs of Interventional Procedures

over 29 years ago

Article

Patterns of Antidepressant Use and Their Relation to Costs of Care

over 29 years ago

Article

Comparison of a Decision Analytic Model with Results from a Naturalistic Economic Clinical Trial: An Application to Evaluating Alternative Antidepressants

over 29 years ago

Article

Comparison of a New Hand-Held Interactive Airway Monitoring System and a Conventional Peak Expiratory Flow Meter in the Management of Asthma

over 29 years ago

Article

The Psychopharmacology of Depression in the Managed Care Setting

over 29 years ago

Article

Cost-Effective Treatment of Depression

over 29 years ago

Article

Correspondence regarding, "HEDIS 3.0: Advancing the State of the Art in Health Plan Performance Measurement"

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Estimating Prevalence and Detection Cost: Prerequisites for Disease State Management of Attention Deficit Hyperactivity Disorder

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Monoclonal Antibodies Had Varying Efficacy in Treating MG